Bellevue Group Ag Ascendis Pharma A/S Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$121.62 - $145.29 $1.89 Million - $2.25 Million	-15,500 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $295,438 - $339,504	2,200 Added 16.54%	15,500 $2.39 Million
Q2 2020 Aug 13, 2020	BUY	$110.87 - $156.01 $155,218 - $218,414	1,400 Added 11.76%	13,300 $1.97 Million
Q1 2020 May 14, 2020	BUY	$97.01 - $145.11 $1.15 Million - $1.73 Million	11,900 New	11,900 $1.34 Million
Q4 2019 Feb 14, 2020	SELL	$91.45 - $139.12 $1.24 Million - $1.89 Million	-13,600 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$95.8 - $118.9 $440,680 - $546,940	-4,600 Reduced 25.27%	13,600 $1.31 Million
Q1 2019 May 15, 2019	BUY	$62.15 - $129.99 $1.13 Million - $2.37 Million	18,200 New	18,200 $2.14 Million

243

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.24B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.